Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group announced that its marketing authorization application for Pertuzumab Injection, a treatment for HER2-positive breast cancer, has been accepted by China’s National Medical Products Administration. The product has shown equivalence in efficacy and safety to existing treatments in clinical trials, potentially strengthening CSPC’s position in the oncology market.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on developing and manufacturing therapeutic biological products, with a particular emphasis on innovative treatments for various medical conditions.
Average Trading Volume: 155,278,643
Technical Sentiment Signal: Buy
Current Market Cap: HK$87.19B
See more insights into 1093 stock on TipRanks’ Stock Analysis page.